Doxorubicin

Doxorubicin Reactions 1704, p147 - 2 Jun 2018 Cardiotoxicity: 15 case reports In a study, 15 patients (10 male and 5 female) aged between 12 67 years were described, who developed anthracyclines- related cardiotoxicity following treatment with chemotherapy regimens containing an anthracycline, doxorubicin [adriamycin, hydroxydaunorubicin] for malignant lymphomas [routes, exact dosages and durations of treatments to reactions onsets not stated]. All the patients, who had stage 1 4 malignant lymphoma (follicular lymphoma, diffuse large B-cell lymphoma or Hodgkin’s lymphoma), received various doxorubicin- containing chemotherapy regimens. Of these, 11 patients received CHOP regimen comprising doxorubicin, cyclophosphamide, vincristine and prednisone, 3 patients received ABVD regimen containing doxorubicin, bleomycin, vinblastine and dacarbazine, and the remaining one patient received Hybrid regimen containing doxorubicin. The total doxorubicin dose administered during chemotherapy ranged between 150 400 [unit not stated]. During or after chemotherapy, a decrease in the ejection fraction was reported in all the patients. A subsequent ECGs of six of these patients showed ST-T changes, while ECGs of the remaining nine patients were normal. A diagnosis of anthracyclines- induced cardiotoxicity was made. The status of cardiotoxicity was acute in 14 patients and it was found to be chronic in 1 patient. Out of 15 patients, 7 patients had symptomatic cardiotoxicity while 8 patients had asymptomatic cardiotoxicity. All patients had completed their scheduled 3 8 cycles of the chemotherapy. However, only one of these patients required doxorubicin dose adjustment. Pharmacological intervention was required in seven of these patients. An improvement was reported in 11 patients, while four patients reported no improvement in the cardiotoxicity. Out of these 15 patients, one patient died on 29 September 2012 due to the underlying cancer (follicular lymphoma). Author comment: "In the present study, a total of 15 patients with anthracyclines related cardiotoxicity were evaluated." Vinodhini MT, et al. Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity. Indian Heart Journal 70: 319-322, No. 2, Mar-Apr 2018. Available from: URL: https://doi.org/10.1016/j.ihj.2017.07.001 - India 803324068 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Doxorubicin

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/doxorubicin-R8l61W62zg
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46790-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p147 - 2 Jun 2018 Cardiotoxicity: 15 case reports In a study, 15 patients (10 male and 5 female) aged between 12 67 years were described, who developed anthracyclines- related cardiotoxicity following treatment with chemotherapy regimens containing an anthracycline, doxorubicin [adriamycin, hydroxydaunorubicin] for malignant lymphomas [routes, exact dosages and durations of treatments to reactions onsets not stated]. All the patients, who had stage 1 4 malignant lymphoma (follicular lymphoma, diffuse large B-cell lymphoma or Hodgkin’s lymphoma), received various doxorubicin- containing chemotherapy regimens. Of these, 11 patients received CHOP regimen comprising doxorubicin, cyclophosphamide, vincristine and prednisone, 3 patients received ABVD regimen containing doxorubicin, bleomycin, vinblastine and dacarbazine, and the remaining one patient received Hybrid regimen containing doxorubicin. The total doxorubicin dose administered during chemotherapy ranged between 150 400 [unit not stated]. During or after chemotherapy, a decrease in the ejection fraction was reported in all the patients. A subsequent ECGs of six of these patients showed ST-T changes, while ECGs of the remaining nine patients were normal. A diagnosis of anthracyclines- induced cardiotoxicity was made. The status of cardiotoxicity was acute in 14 patients and it was found to be chronic in 1 patient. Out of 15 patients, 7 patients had symptomatic cardiotoxicity while 8 patients had asymptomatic cardiotoxicity. All patients had completed their scheduled 3 8 cycles of the chemotherapy. However, only one of these patients required doxorubicin dose adjustment. Pharmacological intervention was required in seven of these patients. An improvement was reported in 11 patients, while four patients reported no improvement in the cardiotoxicity. Out of these 15 patients, one patient died on 29 September 2012 due to the underlying cancer (follicular lymphoma). Author comment: "In the present study, a total of 15 patients with anthracyclines related cardiotoxicity were evaluated." Vinodhini MT, et al. Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity. Indian Heart Journal 70: 319-322, No. 2, Mar-Apr 2018. Available from: URL: https://doi.org/10.1016/j.ihj.2017.07.001 - India 803324068 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off